Cardamyst (Etripamil)

Etripamil is a nasal spray for adults who get sudden episodes of a fast heartbeat called PSVT. People can use it themselves when an episode starts. It works by slowing the electrical signals in the heart so the heartbeat can go back to normal.

Brand names:Cardamyst
Medication

What people taking Cardamyst (Etripamil) report

Every report comes from a Lived member, sent anonymously.

Have you tried Cardamyst (Etripamil) for SVT (Supraventricular Tachycardia)?

NameHow it went

About Cardamyst (Etripamil)

What It's For

Etripamil, sold as Cardamyst, is a prescription nasal spray that adults can use on their own to stop an episode of paroxysmal supraventricular tachycardia (PSVT). PSVT is a type of abnormally fast heartbeat that starts and stops suddenly, often bringing a racing or pounding heart, lightheadedness or shortness of breath. Etripamil was approved in the US in 2025 so that people with a known PSVT diagnosis can treat an episode themselves, wherever they are, without medical supervision. It is meant for treating an episode when it happens, not for preventing future episodes, and it does not replace a longer-term plan for managing PSVT with a cardiologist.

How It Works

In the kind of PSVT etripamil treats, an electrical signal gets caught in a loop that runs through the atrioventricular (AV) node, the small relay point that passes signals from the heart's upper chambers to its lower chambers. Each lap of the loop triggers another heartbeat, which is why the rate jumps suddenly and stays high. Etripamil is a calcium channel blocker, in the same family as verapamil. By blocking calcium from entering cells in the AV node, it slows how quickly signals pass through. That can break the loop and let the heart's normal pacemaker take over again. Because it is sprayed into the nose, it is absorbed within minutes, and its effect fades over the following hour or so.

Dosage & Administration

Cardamyst comes as a pack of two single-use nasal spray devices. Each device gives one spray into each nostril, and those two sprays together make one 70 mg dose. Use it as soon as possible after a PSVT episode starts, sitting down in a place where a fall is unlikely. Do not test spray or prime the device beforehand, since that wastes the dose; throw each device away after use. If symptoms are still present 10 minutes after the first dose, use the second device the same way. Do not use more than two doses (140 mg) in 24 hours. If symptoms have not improved 20 minutes after the second dose, call the care team or get emergency help. Chest pain, severe trouble breathing or fainting during an episode needs emergency help right away; do not wait to see whether the second dose works.

Side Effects

Most side effects come from where the spray lands. Nasal discomfort was by far the most common, affecting roughly a quarter of people in studies, followed by a stuffy or runny nose, throat irritation, watery eyes, sneezing and nosebleeds. Because etripamil lowers blood pressure and slows the heart's electrical conduction, it can cause dizziness or fainting. That risk is higher in people who have fainted before, especially during a PSVT episode, or who have certain heart rhythm problems. This is why the dose is taken sitting down. If someone faints, they should be laid flat, and they need emergency help if they do not recover quickly.

Interactions & Warnings

Etripamil should not be used by people with heart failure that causes symptoms with ordinary activity or at rest (NYHA class II to IV); Wolff-Parkinson-White syndrome, Lown-Ganong-Levine syndrome or other pre-excitation, meaning an electrocardiogram (ECG) shows signs of an extra electrical pathway in the heart; sick sinus syndrome without a pacemaker; or second-degree Mobitz type 2 or more advanced heart block. Slowing the heart's electrical signals can be dangerous in these conditions, so the prescriber checks for them, typically with an ECG, before prescribing etripamil. In studies, many people already took beta blockers or other calcium channel blockers to prevent episodes and used etripamil safely, but the prescriber should still know every heart and blood pressure medicine you take. Safety has not been established in children. There are no data on use in pregnancy, so discuss pregnancy or pregnancy plans with the prescriber. After a dose, people who are breastfeeding should pump and discard milk for 12 hours, because it is not known whether etripamil passes into milk (a related drug, verapamil, does), and it could lower an infant's heart rate or blood pressure.

What to Expect

In the main study, in which people treated episodes at home, about two out of three confirmed PSVT episodes returned to a normal rhythm within 30 minutes with etripamil, compared with about one in three with a placebo spray. The typical time to conversion was around 17 minutes, versus nearly an hour with placebo. Most people in that study used the second dose. So etripamil does not stop every episode, and having a backup plan matters. Not every racing heartbeat is PSVT: in the same study, about one in five episodes people treated turned out to be another rhythm. Reviewing episodes with the cardiologist, including any heart rhythm recordings, helps confirm that the spray is being used for the right problem. Keep track of how often episodes occur and how they respond, since frequent episodes are worth discussing as a reason to look at longer-term treatment.

Questions to Ask Your Doctor

  1. 1.How sure are we that my episodes are PSVT, and do I have any heart condition that would make etripamil unsafe?
  2. 2.Should my first dose be taken somewhere I can be monitored, given my blood pressure and any fainting history?
  3. 3.What should I do first when an episode starts, and at what point should I use the spray or go to the emergency department?
  4. 4.How does etripamil fit with my other heart medicines, and should we also consider a longer-term treatment to prevent episodes?
  5. 5.What should I record during an episode so we can review how well the spray worked?

Last reviewed • Oct 2026

Educational content, not medical advice.